+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Peripheral artery disease, sometimes called PAD, happens when the arteries in the legs or arms become narrowed or blocked by fatty deposits, reducing blood flow. This can cause pain when walking, slow healing of wounds, and in severe cases, risk of l...

Search Bar & Filters

Found 245 Actively Recruiting clinical trials

U

Actively Recruiting

Researchers are evaluating whether using an automated Carbon Dioxide CO2 injection system during infrainguinal peripheral vascular interventions PVI can reduce major adverse kidney events within 90 days in patients at moderately increased risk for contrast-associated acute kidney injury CA-AKI. This Phase 3 randomized controlled trial compares a CO2-based contrast medium sparing strategy to the standard use of iodinated contrast media in patients with peripheral vascular and kidney diseases. Participants are randomly assigned to one of two groups. The intervention group receives PVI using an automated CO2 injection system as the primary contrast agent, with iodinated contrast media available as a backup if image quality is insufficient or if the patient cannot tolerate CO2 angiography. The control group undergoes routine PVI using iodinated contrast media according to local standards, avoiding high-osmolar contrast agents. All patients are followed for up to 12 months after their procedure. During the study, participants undergo the planned PVI procedure with either contrast method. Researchers carefully record the amount and reasons for any iodinated contrast media used in the CO2 group. Patients are monitored for kidney-related outcomes, focusing on major adverse kidney events up to 90 days after the intervention. The trial includes ongoing follow-up assessments to evaluate safety and effectiveness over one year.

Age: 18Years +All GendersPhase 3
11 locations
S

Actively Recruiting

Healthy Volunteer

This trial investigates ATI-1013, a drug being studied in healthy adult cigarette smokers to understand its safety, how long it stays in the body, whether it causes an immune response, and its effects on nicotine levels. The study compares ATI-1013 to a placebo to evaluate safety and how the drug interacts with nicotine. It is a first-in-human, phase 1 clinical trial conducted by Antidote Therapeutics, Inc. Participants receive one intravenous infusion of ATI-1013 at one of three escalating doses 0.2 g, 0.8 g, or 3.2 g or a placebo. The study uses a randomized, double-blind design with a 41 ratio favoring ATI-1013 in each dose group. The trial includes a screening period, a dosing day with at least 48 hours of in-clinic observation, and follow-up visits on Days 7, 21, 42, 56, and 84, plus telephone check-ins on Days 5, 14, 28, and 70. Participants keep a diary of their cigarette use and smoking habits. Researchers monitor adverse events, immune responses, and drug levels in the blood over 84 days. They also track nicotine-related physiological responses such as skin temperature, heart rate, blood pressure, and withdrawal symptoms, along with subjective effects of nicotine. Safety and drug behavior in the body are key outcomes throughout the study period.

Age: 23Years - 59YearsAll GendersPhase 1
1 location
S

Actively Recruiting

Ischemic cerebrovascular disease is a leading cause of death and disability worldwide. This study investigates a new parameter derived from Digital Subtraction Angiography DSA to evaluate cerebral blood flow and predict outcomes in patients with cerebral ischemia, specifically acute stroke with large vessel occlusion. Researchers aim to understand the relationship between this new DSA-based perfusion parameter and patient outcomes measured by the modified Rankin Scale. The study is observational and analyzes images from patients who have undergone DSA. Participants are classified based on their cerebral perfusion levels into good, middle, or poor perfusion groups using this new parameter. The study does not involve interventions but focuses on evaluating and comparing outcomes among these groups. Participants DSA images and follow-up data on their clinical outcomes, collected between 3 months and 2 years after the procedure, will be analyzed. The main outcome measured is the difference in recovery and disability levels between patients with good and poor perfusion. Additional comparisons between good and middle perfusion groups will also be reviewed. The study is conducted by Xian No.3 Hospital and will continue until July 2038.

All AgesAll Genders
1 location
S

Actively Recruiting

Researchers are investigating the safety and effectiveness of the Renzan14 Peripheral Stent System in treating patients with femoro-popliteal disease, a type of peripheral arterial disease affecting the leg arteries. This prospective, multicenter, single-arm study plans to include about 100 patients eligible for treatment with this stent. The study focuses on evaluating a modern nitinol stent designed for complex lesions where drug-coated balloons and drug-eluting stents may be less effective or raise concerns about toxicity. The Renzan stent is a self-expanding nitinol device pre-mounted on a catheter designed for precise placement in the affected arteries. It consists of two layers of braided nitinol wire mesh with radiopaque markers to assist in positioning during the procedure. The stent can be partly recaptured during placement if needed. This study observes patients undergoing endovascular implantation of the Renzan stent without comparison groups, focusing on the devices performance and safety after treatment. Participants will be followed for assessments of safety and effectiveness, including measurements at 30 days and up to 12 months after the procedure. Key evaluations include device and procedural success during implantation, rates of death, need for further treatment of the treated artery, artery openness, limb ischemia improvement, major adverse events, and limb amputation at multiple time points up to 36 months. Patients will be monitored closely with follow-up visits to track these outcomes and the long-term performance of the stent.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating two imaging strategies to improve the treatment of patients with significant calcified coronary artery disease undergoing percutaneous coronary intervention PCI. The study compares a non-invasive coronary CT angiography CCTA-guided calcium modification approach with the current standard intravascular ultrasound IVUS-guided PCI to see if CCTA can enhance procedural efficiency and outcomes while maintaining similar safety. This prospective, multicenter, randomized controlled trial involves 700 patients with flow-limiting stenosis and moderate-to-severe calcification. Participants are randomly assigned to one of two groups one uses CCTA-guided calcium modification, which applies advanced CT imaging to plan and select plaque modification techniques before PCI the other uses IVUS-guided calcium modification following established intravascular ultrasound criteria for plaque preparation and stent optimization. Both groups receive post-procedural IVUS to confirm correct stent implantation. The study measures superiority in final minimal stent area and non-inferiority in 12-month target vessel failure. During the study, participants undergo pre-procedural imaging with either CT or IVUS to assess lesion characteristics. Researchers will evaluate procedure time, radiation exposure, contrast volume, stent area measurements, number of calcium fractures, and clinical safety outcomes including myocardial infarction and stent thrombosis. Patient-reported angina symptoms will also be tracked. The trial continues with follow-up assessments for 12 months to monitor clinical outcomes and safety, with the total participation lasting up to one year post-procedure.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
15 locations
R

Actively Recruiting

Researchers are gathering detailed real-world information on people with chronic wounds and ulcers to better understand their medical journey and treatment outcomes. This observational registry collects data from over 1,400 healthcare providers across the USA and Puerto Rico using a specialized electronic health record system. It includes all major wound types such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, surgical wounds, traumatic wounds, and inflammatory ulcers. Participants receive care as usual from their clinicians, who use standard and advanced wound treatments like specialized dressings, compression therapy, offloading devices, cellular and tissue-based products, negative pressure therapy, ultrasound therapy, topical oxygen, hyperbaric oxygen, growth factors, debridement, and topical antibiotics. Data on treatment practices, wound characteristics, patient health conditions, and complications are collected continuously during routine care. Patients may be followed for over five years to track long-term outcomes. During the study, researchers collect information on patient demographics, wound details, treatment methods, visit frequency, and complications. They monitor healing progress, amputations, deaths, wound recurrence, hospitalizations, and other outcomes. The registry uses a wound healing index to adjust for risk and supports quality improvement and research by linking clinical data with insurance claims for comprehensive analysis. This ongoing effort helps to better understand wound healing and treatment effectiveness in everyday healthcare settings.

All AgesAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the Passeo-18 Lux paclitaxel-releasing percutaneous transluminal angioplasty PTA balloon catheter for treating new or recurring cholesterol-related blockages in the arteries of the lower leg. This device has been previously studied for safety and effectiveness and is approved for use in Europe, meeting European Union safety and performance standards. The trial focuses on gathering additional information about its performance and safety in everyday medical care, especially for longer balloon lengths. All participants in this single-group trial will receive treatment with the Passeo-18 Lux drug-coated balloon, which is available in various sizes. The treatment involves using this balloon catheter during angioplasty to address lesions in the infrainguinal arteries. The study will observe how well the device delivers, inflates, deflates, and is retrieved during the procedure, and will monitor lesion restoration after treatment. Participants will be followed for up to 12 months after the procedure to assess freedom from clinically-driven target lesion revascularization and major adverse events. Additional follow-ups will continue up to 60 months to monitor outcomes like survival without amputation, quality of life changes, walking ability, and lesion patency. Various clinical assessments, questionnaires, and angiograms will be conducted during scheduled visits to evaluate safety and effectiveness over time.

Age: 18Years - 99YearsAll GendersPhase Not Applicable
4 locations
P

Actively Recruiting

Researchers are evaluating the effects of SRSD107 in adults with chronic coronary artery disease CAD andor peripheral arterial disease PAD. This Phase 2a study aims to understand how multiple doses of SRSD107 affect the body pharmacodynamics, how the body processes the drug pharmacokinetics, and its safety when used alongside aspirin therapy. The trial uses a randomized, double-blind, placebo-controlled design with several sequential groups to carefully assess these factors. Participants will receive subcutaneous injections of SRSD107 at different dose levels or a placebo. The study includes five groups four experimental dose levels of SRSD107 and one placebo group. All treatments are administered under close monitoring to assess drug levels and effects over time. Throughout the 72-week study period, participants will have regular assessments including blood tests to measure FXI antigen levels, FXI activity, and clotting times aPTT. Researchers will also track how much SRSD107 is present in the blood, the timing of peak concentrations, and any adverse events. Safety and drug effects will be carefully monitored to understand how SRSD107 works in this patient population.

Age: 18Years - 75YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are conducting a prospective, multicenter, randomized trial to assess the effectiveness and safety of the Sperstent peripheral spot stent system compared to the Everflex self-expanding peripheral stent system. The study focuses on treating residual lesions such as stenoses and dissections that remain after balloon angioplasty in the femoral and proximal popliteal arteries. These conditions are common in patients with peripheral arterial disease and affect blood flow in the legs. Participants will receive either the Sperstent peripheral spot stent system or the Everflex self-expanding peripheral stent system during endovascular treatment following percutaneous transluminal angioplasty PTA. Both treatments involve placing a stent to open narrowed or blocked arteries, guided by digital subtraction angiography DSA. The trial compares these two devices to understand their impact on artery patency and safety over time. Throughout the study, participants will be closely monitored with follow-up assessments including imaging to check artery openness, clinical evaluations of symptoms using Rutherford classification and ankle-brachial index ABI, and tracking of major adverse events. Key outcomes include primary patency at 12 months and freedom from major adverse events at 30 days after the procedure. The study period includes evaluations immediately after treatment and at 30 days, 6 months, and 12 months to monitor device success, procedural success, and changes in clinical status.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
12 locations
S

Actively Recruiting

Researchers are evaluating the safety and performance of the Acotec Litos & Tulip Drug-coated Balloon DEB catheters for treating lesions in below-the-knee arteries in people with Peripheral Artery Disease. This prospective, multi-center, single arm study aims to gather detailed data on how well this device works and its safety when used for this condition. Participants are adults aged 18 to 75 with specific artery blockage conditions affecting blood flow below the knee. Participants will receive treatment using the DEB catheter, either the AcoArt Tulip 0.018 or AcoArt Litos 0.014 model, to address stenosis or occlusions in below popliteal arteries. This single arm study means all participants receive the study device without comparison groups. The treatment targets significant artery narrowing or blockages to improve blood flow. The study does not mention placebo or alternative treatments. During the study, participants will be monitored through regular follow-up visits to evaluate the primary outcome of artery patency at 6 months. Secondary outcomes include major adverse event rate at 30 days, patency rates up to 60 months, rates of major limb amputation, mortality, vessel and lesion revascularization, ulcer healing, and distal embolization rates. Participants will undergo examinations and assessments specified by the protocol to track their response to the treatment and safety over time. The study is expected to continue until April 2027.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location

1-10 of 245

1

Frequently Asked Questions